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Abstract
The serotonergic (5-HT) neuronal system has important and diverse physiological functions throughout development and
adulthood. Its dysregulation during development or later in adulthood has been implicated in many neuropsychiatric
disorders. Transgenic animal models designed to study the contribution of serotonergic susceptibility genes to
a pathological phenotype should ideally allow to study candidate gene overexpression or gene knockout selectively in
serotonergic neurons at any desired time during life. For this purpose, conditional expression systems such as the tet-
system are preferable. Here, we generated a transactivator (tTA) mouse line (TPH2-tTA) that allows temporal and spatial
control of tetracycline (Ptet) controlled transgene expression as well as gene deletion in 5-HT neurons. The tTA cDNA was
inserted into a 196 kb PAC containing a genomic mouse Tph2 fragment (177 kb) by homologous recombination in E. coli.
For functional analysis of Ptet-controlled transgene expression, TPH2-tTA mice were crossed to a Ptet-regulated lacZ
reporter line (Ptet-nLacZ). In adult double-transgenic TPH2-tTA/Ptet-nLacZ mice, TPH2-tTA founder line L62-20 showed
strong serotonergic b-galactosidase expression which could be completely suppressed with doxycycline (Dox).
Furthermore, Ptet-regulated gene expression could be reversibly activated or inactivated when Dox was either withdrawn
or added to the system. For functional analysis of Ptet-controlled, Cre-mediated gene deletion, TPH2-tTA mice (L62-20) were
crossed to double transgenic Ptet-Cre/R26R reporter mice to generate TPH2-tTA/Ptet-Cre/R26R mice. Without Dox, 5-HT
specific recombination started at E12.5. With permanent Dox administration, Ptet-controlled Cre-mediated recombination
was absent. Dox withdrawal either postnatally or during adulthood induced efficient recombination in serotonergic neurons
of all raphe nuclei, respectively. In the enteric nervous system, recombination could not be detected. We generated
a transgenic mouse tTA line (TPH2-tTA) which allows both inducible and reversible transgene expression and inducible Cre-
mediated gene deletion selectively in 5-HT neurons throughout life. This will allow precise delineation of serotonergic gene
functions during development and adulthood.
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Introduction
Serotonin (5-HT) is the most mysterious of the main
neuromodulators [1]. It appears to tune nearly all behaviours
and physiological processes [2] and dysfunction of 5-HT neurons
has been implicated in many neuropsychiatric disorders with
diverse psychopathology [3]. Studies have indicated that the
developmental timing of 5-HT disturbances together with gene-
environment interactions is critical for observed changes in
behaviour [4,5,6,7,8].
To delineate developmental and adult 5-HT specific gene
effects on a wide spectrum of functions such as impulsivity/
behavioural disinhibition, affective control, decision making or
reinforcement learning, the ability for temporal and spatial control
of gene manipulation in transgenic mouse models is a prerequisite.
This is particularly important when timely manipulations of the 5-
HT system are to be combined with specific environmental
interventions such as maternal deprivation or housing isolation
during development or adulthood.
Two widely used conditional transgenic systems allow for
inducible, tissue-specific target gene manipulation, i.e. the
tetracycline-inducible (tet-) system [9] and the CreERT/loxP-
system [10]. In most cases, the CreERT/loxP-system is used for
inducible gene knockouts although it also allows for inducible gene
expression [11]. Vice versa, the tet-system is widely used for
inducible and reversible expression of candidate genes albeit
temporal control of tissue-specific gene deletion is also possible
[12].
Inducible and reversible gene expression via the tet-system
requires the generation of double-transgenic mice by mating
a ‘‘transactivator line’’ with a ‘‘tet-response line’’. In the
transactivator line, a tissue specific promoter (TSP) controls the
expression of an artificial transcription factor, the tetracycline
transactivator (tTA or rtTA). In the tet-response line, a tet-
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(GOI). In double-transgenic TSP-tTA/Ptet-GOI mice, tissue-
specific transactivator expression leads to Ptet-controlled transcrip-
tion of the GOI which can be regulated by administration of
doxycycline (Dox). The tet-off system, which was applied in this
study, makes use of the tTA which can only bind and activate Ptet-
controlled gene expression in the absence of Dox. In particular, the
tet-system is suitable for reversible gene manipulations [13], which
can not be accomplished with the Cre/loxP system where Cre-
mediated recombination of loxP flanked sequences is irreversible.
Finally, mating tissue-specific tTA mice with Ptet-Cre/loxP-
flanked target gene mice allows spatially controlled, inducible gene
deletion [12].
Here, we applied the tet-system to achieve inducible Ptet-
controlled transgene expression specifically in 5-HT neurons. A
177 kb genomic Tph2 sequence was chosen as an element to
regulate tissue specific expression of tTA throughout life.
Functional analysis of TPH2-tTA founder lines confirmed adult
5-HT neuron specific expression of the reporter gene lacZ in eight
of eleven TPH2-tTA lines. TPH2-tTA founder L62-20 showed
inducible and reversible Ptet-controlled b-galactosidase (bgal)
expression in the majority of 5-HT neurons. Furthermore, Ptet-
controlled Cre-mediated recombination allows efficient and
temporally tightly controlled gene deletion as shown with triple-
transgenic TPH2-tTA/Ptet-Cre/R26R mice. Hence, the TPH2-
tTA line allows both inducible, 5-HT specific gene expression and
gene knockout illustrating the versatility of this system to
manipulate candidate genes bidirectionally.
Results
Generation of Transgenic Mice Expressing tTA in
Serotonergic Neurons
Regulatory elements of the mouse Tph2 locus were chosen to
achieve spatial control of tTA expression in serotonergic neurons
of the brain. We selected a PAC harbouring a 177 kb genomic
insert containing the entire Tph2 gene (107 kb) with additional 59
upstream (51 kb) and 39 downstream (19 kb) sequences. To
generate the TPH2-tTA transgene the tTA coding sequence was
inserted in place of the ATG-start of the Tph2 gene (Fig. 1) by
homologous recombination in bacteria [14]. The modified
genomic insert was introduced into the mouse germline of
BDF1-mice (Charles River) by oocyte injections. 17 transgenic
TPH2-tTA founders were identified by PCR-genotyping of tail
DNA. Of those, 11 transmitted their transgene to the next
generation and were further characterized.
In situ Hybridization of tTA Expression in TPH2-tTA
Founder Mice
First, we investigated tTA mRNA expression by non-radioactive
in situ-hybridization (ISH) on coronal vibratome sections of the
brain using a specific antisense tTA probe. Nine of eleven TPH2-
tTA lines showed tTA mRNA expression in the brain stem and
midbrain where serotonergic neurons are located (Fig. 2). All tTA-
mRNA positive TPH2-tTA lines were crossed with Ptet-nLacZ
reporter mice [15] to functionally assess Ptet-regulated reporter
gene expression (Fig. 3).
Functional Characterization of Adult TPH2-tTA Founder
Mice
Initial functional characterization of all TPH2-tTA lines was
conducted without Dox to keep the tet-system permanently active
(Fig. 3). Adult TPH2-tTA/Ptet-nLacZ mice, 2–3 months of age,
were sacrificed for analysis. In all founder lines, X-Gal staining of
TPH2-tTA/Ptet-nLacZ mice detected bgal activity in the brain
stem and mid brain which are the neuroanatomical areas where
serotonergic neurons are located (Fig. 4A,C,E). Dual-label
fluorescence immunohistochemistry (IHC) with bgal and trypto-
phan hydroxylase 2 (TPH2) antibodies was performed to
investigate tissue-specificity and expression levels of Ptet-controlled
bgal in serotonergic neurons. While bgal expression confirms
successful tTA-induction of Ptet-controlled lacZ transcription,
TPH2 antibodies detect the tryptophan hydroxylase 2 (TPH2)
which is the rate-limiting enzyme of brain 5-HT synthesis and
consistently found in all serotonergic neurons of the raphe nuclei
[16]. Dual-label fluorescence IHC confirmed that Ptet-controlled
bgal expression occurred selectively in 5-HT neurons (Fig. 4B,D,F).
With the exception of line L62-31 which showed aberrant
expression outside the raphe nuclei, all other founder lines were
negative for X-Gal staining in extraserotonergic brain regions.
Nonetheless, the amount of bgal expression differed significantly
among TPH2-tTA founder lines and even among TPH2-tTA/
Ptet-nLacZ offspring from the same TPH2-tTA line.
As a consequence, we decided to extensively study the eight
remaining 5-HT neuron specific TPH2-tTA founder lines. Since
developmental Ptet-controlled transgene suppression in the
presence of Dox is a desired feature in the tet-off system, we
performed all further analysis with Dox suppression during
development until P60. Hereafter, Dox was withdrawn to induce
Ptet-controlled transgene expression and mice were sacrificed for
analysis at P90. Each TPH2-tTA founder line was crossed to
homozygous Ptet-nLacZ mice to generate large numbers of
TPH2-tTA/Ptet-nLacZ offspring. Adult offspring from 2–3
different matings (TPH2-tTA6Ptet-nLacZ) were analyzed in-
dividually for bgal expression (n =5–14 mice for each line). Every
TPH2-tTA founder line showed tissue-specific bgal expression in
serotonergic neurons (Table 1). Nonetheless, in several TPH2-tTA
lines (L62-22, L62-26, L62-29, L62-30, L62-34) we found highly
variable, serotonergic bgal expression among offspring. This is an
undesired feature as this would lead to highly unpredictable
candidate gene expression in individual mice during experiments.
In contrast, in the three remaining founder lines (L62-1, L62-20,
L62-25) the level of 5-HT neuron specific bgal expression among
TPH2-tTA/Ptet-nLacZ offspring was relatively stable while the
absolute efficiency of bgal expression in 5-HT neurons (bgal+/
TPH2+ of all TPH2+ neurons) varied significantly among these
lines (Table 1). Line 62-20 displayed the highest level of overall
Figure 1. TPH2-tTA construct for DNA microinjection. A PCR-
amplified tTA.pA sequence which contains flanking sequences (42 bp)
homologous to the integration site of the PAC-based mouse Tph2 gene
was used for homologous recombination in E.coli. The construct was
recombined into the ATG-start of Exon 1 of Tph2, thereby deleting
a 23 bp sequence containing additional in-frame ATG sites.
doi:10.1371/journal.pone.0038193.g001
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neurons, 95%-CI: 80–82%) together with low variability of bgal
expression among double-transgenic offspring (Table 1). When
subdivided, 93%, 81% and 71% of all TPH2+ neurons were bgal+
in the caudal, dorsal and median raphe nuclei, respectively (95%-
Confidence interval (CI): caudal 90–95%, dorsal 80–83%, median
67–74%) (Table 1). Based on these findings, TPH2-tTA line 62-20
was selected for all further experiments.
Inducible and Reversible Tissue Specific bgal Expression
in TPH2-tTA/Ptet-nLacZ Mice
The tet-system allows for inducible and reversible gene
expression (Fig. 3) which is a unique hallmark of this system
and clearly distinguishes it from other conditional systems based
on recombinases (Cre, Flp). Hence, the TPH2-tTA line L62-20
was further tested for inducibility and reversibility of Ptet-
controlled reporter gene expression (Table 2; Fig. 5). Using the
tet-off system, inducible gene expression requires permanent
Dox treatment to suppress gene expression prior to induction/
activation without Dox (+/2Dox). In contrast, reversible gene
expression requires a previously activated system to be shut
down with Dox (2/+Dox). While suppression of Ptet-controlled
gene expression with Dox is rapidly achieved using the tet-
system, activation of gene expression after Dox withdrawal may
require up to several weeks. After permanent Dox administra-
tion until P60, partial activation of Ptet-controlled gene
expression in TPH2-tTA/Ptet-nLacZ mice was detectable after
7 days whereas maximal Ptet-controlled gene expression was
achieved after 3 weeks (data not shown). As a consequence, in
the subsequent analysis activation and reactivation was mea-
sured 30 days after Dox withdrawal.
To analyze inducible and reversible gene expression in detail,
the first group of double-transgenic mice was given Dox
permanently during development and early adulthood until
sacrifice at P90 (+Dox) to analyze chronic suppression of Ptet-
regulated gene expression (Table 2: protocol 1; Fig. 5A,F,K) In
protocol 2, mice which had not received Dox during development
until P60 were given Dox until sacrifice at P90 (2/+Dox) to
analyze reversibility of previously activated gene expression n
during development (Table 2: protocol 2; Fig. 5B,G,L). In protocol
3, mice were given Dox during embryonic and postnatal
development until P60 when Dox was withdrawn until sacrifice
at P90 (+/2Dox) to test for inducible Ptet-controlled gene
activation during adulthood (Table 2: protocol 3; Fig. 5C,H,M).
Figure 2. Non radioactive in-situ hybridization of TPH2-tTA
founder lines. A tTA-antisense probe was used to detect tTA-mRNA in
transgenic TPH2-tTA mice. Each TPH2-tTA line was screened by non-
radioactive ISH. (A-C) Exemplary tTA in situ hybridization of founder line
62-20 showed abundant tTA-mRNA in brain stem and midbrain areas
where raphe nuclei with serotonergic neurons are located. CR, caudal
raphe nuclei; DR, dorsal raphe nuclei; MR, median raphe nuclei.
doi:10.1371/journal.pone.0038193.g002
Figure 3. Functional characterization of Ptet-controlled bgal
expression in TPH2-tTA/Ptet-nLacZ mice. TPH2-tTA mice were
mated with Ptet-nLacZ mice to generate double-transgenic TPH2-tTA/
Ptet-nLacZ mice. In Ptet-nLacZ reporter mice, a bidirectional promoter
Ptetbi which contains seven tet operator sequences flanked by two
minimal promoters [77] allows bidirectional Ptet-controlled transcrip-
tion of nuclear localized lacZ and luciferase cDNA. Only bgal reporter
expression was analyzed in TPH2-tTA/Ptet-nLacZ mice. In the presence
of Dox (+Dox), bgal expression is not initiated since tTA binding to Ptet
is prevented by Dox. In the absence of Dox (-Dox), tTA binds to Ptet
which activates lacZ reporter gene transcription.
doi:10.1371/journal.pone.0038193.g003
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given Dox again from P90 until sacrifice at P120 (+/2/+ Dox) to
analyze for reversibility of induced Ptet-controlled gene expression
during adulthood (Table 2: protocol 4; Fig. 5D,I,N). In protocol 5,
mice received the same protocol as in 4 but Dox was withdrawn
again from P120 until sacrifice at P150 (+/2/+/2 Dox) to test for
Figure 4. 5-HT neuron-specific transgene expression in TPH2-tTA/Ptet-nLacZ mice. Exemplary results from TPH2-tTA line L62-20 mated
with Ptet-nLacZ mice to generate double-transgenic TPH2-tTA/Ptet-nLacZ mice which never received Dox. Adult mice (P90) were sacrificed and
analyzed with X-Gal staining and IHC. (A,C,E) Without Dox administration, X-Gal staining of coronal sections of brain stem and midbrain showed
intense bgal activity in the raphe nuclei where 5-HT neurons reside. (B,D,F) Dual-label fluorescence IHC with bgal and 5-HT neuron-specific TPH2
antibodies. Co-labelling indicates 5-HT neuron-specific bgal transgene expression. IHC confirmed that bgal expression occurred tissue-specifically in
the majority of all 5-HT neurons (B,D,F). Grey arrowheads show scarce bgal-negative TPH2+5-HT neurons. Scale bars: 100 mm.
doi:10.1371/journal.pone.0038193.g004
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5; Fig. 5E,J,O). All mice were sacrificed at the respective points in
time and brain sections were analyzed with X-Gal staining (X-Gal)
and dual-label immunohistochemistry (IHC) for Ptet-controlled
reporter gene (bgal) expression.
A prerequisite for inducible gene expression with the tet-off
system is its suppressibility with Dox. We show that Ptet-controlled
serotonergic gene expression could be fully suppressed with
chronic Dox administration (Table 2: protocol 1, Fig. 5A,F,K).
Equally important, under all tested conditions, bgal expression
could be completely reversed with Dox administration (Table 2:
protocol 2 and 4), irrespective of previous activation during
development (Table 2: protocol 2; Fig. 5B,G,L) or adulthood
(Table 2: protocol 4; Fig. 5D,I,N). Vice versa, induction of Ptet-
controlled gene expression was always feasible, regardless whether
gene expression was previously suppressed with Dox during
development (Table 2: protocol 3; Fig. 5C,H,M) or adulthood
(Table 2: protocol 5; Fig. 5E,J,O). Thus, Ptet-controlled gene
expression in the 5-HT neuronal system can be manipulated at
will in all possible combinations, as gene expression can be
repeatedly induced and/or reversed at any time during the
animal’s life.
Tight Control of Tissue-specific Recombination in TPH2-
tTA/Ptet-Cre/R26R Mice During Development and
Adulthood
Heretofore, we showed that TPH2-tTA mice permit tissue-
specific, inducible and reversible Ptet-controlled gene expression in
Table 1. Efficiency of Ptet-controlled bgal expression in TPH2-tTA/Ptet-nLacZ offspring of eight independent TPH2-tTA founder
lines.
Line
No. of analyze
offspring
absolute frequency
(bgal+/TPH2+):TPH2+
relative frequency
(bgal+/TPH2+):TPH2+
range of relative
frequency 95% CI
L62-1 CR 268:407 66% 52–78% 61–70%
L62-1 DR 1161:2596 45% 37–50% 43–47%
L62-1 MR 152:483 31% 18–54% 27–36%
L62-1 total 7 1581:3486 45% 38–53% 44–47%
L62-20 CR 494:533 93% 89–96% 90–95%
L62-20 DR 2587:3186 81% 72–89% 80–83%
L62-20 MR 486:686 71% 63–86% 67–74%
L62-20 total 9 3567:4405 81% 74–89% 80–82%
L62-22 CR 376:421 89% 70–100% 86–92%
L62-22 DR 1353:2081 65% 40–83% 63–67%
L62-22 MR 277:535 52% 30–65% 47–56%
L62-22 total 10 2006:3037 66% 42–81% 64–68%
L62-25 CR 79:247 32% 24–38% 26–38%
L62-25 DR 152:1114 14% 5–19% 12–16%
L62-25 MR 53:278 19% 6–33% 15–24%
L62-25 total 5 284:1639 17% 9–23% 16–19%
L62-26 CR 418:467 90% 55–100% 86–92%
L62-26 DR 2765:3419 81% 76–91% 80–82%
L62-26 MR 330:522 63% 36–72% 59–67%
L62-26 total 9 3513:4408 80% 76–85% 79–81%
L62-29 CR 316:512 62% 25–89% 57–66%
L62-29 DR 1162:3493 33% 18–51% 32–35%
L62-29 MR 245:731 34% 19–49% 30–37%
L62-29 total 9 1723:4736 36% 19–53% 35–38%
L62-30 CR 636:742 86% 51–99% 83–88%
L62-30 DR 3470:4266 81% 57–94% 80–83%
L62-30 MR 475:774 61% 35–84% 58–65%
L62-30 total 12 4581:5782 79% 54–89% 78–80%
L62-34 CR 399:830 48% 6–86% 45–52%
L62-34 DR 2456:5332 46% 3–69% 45–47%
L62-34 MR 404:1124 36% 8–69% 33–39%
L62-34 total 14 3259:7286 45% 4–66% 44–46%
TPH2-tTA/Ptet-nLacZ nice which had received Dox throughout development until P60 were sacrificed at P90 after 30 days of Ptet-controlled gene activation without
Dox and analyzed with dual-label IHC. Efficiencies for caudal (CR), median (MR) and dorsal (DR) raphe nuclei were separately and jointly (total) calculated. Confidence-
bounds (CI) were calculated using the Clopper-Pearson method based on significance level 95.0%.
doi:10.1371/journal.pone.0038193.t001
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also allow for inducible gene deletion in combination with the
Cre/loxP system (Table 3). For this purpose, we generated triple-
transgenic TPH2-tTA/Ptet-Cre/R26R mice (Fig. 6). In these
mice, binding of tTA to the Ptet-promoter in the absence of Dox
induces Cre expression (Ptet-Cre) [12]. This in turn leads to Cre
mediated excision of a loxP-flanked stop-cassette in the Rosa26
locus which results in bgal expression (R26R) [17]. Hence, bgal
expression functionally confirms tTA-induced, Ptet-controlled
Cre/loxP recombination.
First, TPH2-tTA/Ptet-Cre/R26R mice which had never re-
ceived Dox were sacrificed between E12.5 and E15.5 to evaluate
whether the transgenic TPH2 regulatory elements adequately
control tTA expression early during development of 5-HT
neurons. At E12.5, TPH2-tTA/Ptet-Cre/R26R mice already
show extensive bgal expression in serotonergic neurons
(Fig. 7A,C,E), one day after TPH2 protein expression in 5-HT
neurons begins [18]. Hence, Ptet-controlled gene expression
during embryonic development is adequately regulated in
TPH2-tTA mice. Consequently, adult TPH2-tTA/Ptet-Cre/
R26R mice which had never received Dox also showed extensive
X-Gal staining in the raphe nuclei (Table 3: protocol 1;
Fig. 8A,E,I). Using dual-label fluorescence IHC against TPH2
and bgal, massive recombination, i.e. bgal expression, in 5-HT
neurons of all raphe nuclei of the brain stem and midbrain during
development could be confirmed (Fig. 8M,Q,U). Extraserotoner-
Table 2. Protocols for inducible and reversible reporter gene
expression in TPH2-tTA/Ptet-nLacZ mice.
Protocol 1: Protocol 2: Protocol 3: Protocol 4: Protocol 5:
+Dox h/+Dox +/h Dox +/h/+ Dox +//+/h Dox
+Dox until
P90
hDox until
P60
+Dox until
P60
+Dox until
P60
+Dox until
P60
+Dox until
P90
hDox until
P90
hDox until
P90
hDox until
P90
+Dox until
P120
+Dox until
P120
hDox until
P150
Dox was administered with 5 mg/ml from initiation of matings until birth. At P0,
Dox concentration was changed to 50 mg/ml. Suppression of Ptet-controlled
gene expression in adult mice was also done with 50 mg/ml Dox. In protocol 1,
mice were maintained under chronic Dox administration throughout life until
sacrifice at P90. In protocol 2, transgenic mice were maintained in the absence
of Dox until P60 when Dox administration was initiated until sacrifice at P90. In
protocol 3, Dox was given from conception until P60 when Dox was withdrawn
until sacrifice at P90. Protocol 4 is based on protocol 3. Here, Ptet-controlled
bgal expression was re-suppressed from P90 until sacrifice at P120. Protocol 5 is
based on protocol 4, but removal of Dox at P120 until sacrifice at P150
reactivated Ptet-controlled bgal expression. +Dox, administration of
Doxycycline; hDox, no administration of Dox.
doi:10.1371/journal.pone.0038193.t002
Figure 5. Inducible and reversible 5-HT neuron-specific transgene expression in TPH2-tTA/Ptet-nLacZ mice. Inducibility and
reversibility of Ptet-controlled transgene expression is a hallmark of the tet-system. To test these potential merits in TPH2-tTA mice, double-
transgenic TPH2-tTA/Ptet-nLacZ mice were generated. Adult mice (.P90) were sacrificed and analyzed with dual-label fluorescence IHC using bgal
and 5-HT neuron-specific TPH2 antibodies. (A,F,K) With permanent Dox administration (+Dox), Ptet-controlled bgal expression could be fully
suppressed in TPH2-tTA/Ptet-nLacZ mice. Furthermore, Ptet-controlled bgal expression was reversible with Dox administration, regardless whether
prior bgal expression occurred during development (2/+Dox; B,G,L) or during adulthood (+/2/+Dox; D,I,N). Vice versa, after chronic Dox
administration during embryonic and postnatal development, Ptet-controlled bgal expression could be fully induced (C,H,M) and re-induced (E,J,O)
via Dox withdrawal. Scale bars: 100 mm.
doi:10.1371/journal.pone.0038193.g005
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staining in the hypothalamus and beneath the aqueduct. Of note,
single bgal+/TPH2-negative cells were identified within the
median raphe nuclei of TPH2-tTA/Ptet-Cre/R26R mice which
had never received Dox (Fig. 8U). With permanent Dox
administration (Table 3: protocol 2), recombination could not be
detected with X-Gal staining and dual-label IHC in TPH2-tTA/
Ptet-Cre/R26R mice at P90 (Fig. 8B,F,J,N,R,V). Hence, Dox
application allows permanent and complete suppression of Ptet-
controlled Cre-mediated recombination throughout development
and adulthood.
Next, we assessed inducible activation of Ptet-controlled, Cre-
mediated gene deletion in 5-HT neurons (Table 3: protocol 3 and
protocol 4). When Dox was given throughout embryogenesis until
P0 and mice were sacrificed at P90, virtually all 5-HT neurons in
adult mice were bgal+, indicating efficient, inducible postnatal
recombination in all raphe nuclei (Table 3: protocol 3;
Fig. 8O,S,W). Interestingly, Dox suppression during embryogen-
esis abolished recombination in TPH2-negative cells in the median
raphe nuclei (Fig. 8W). Furthermore, the minimal extraserotoner-
gic recombination in the hypothalamus and beneath the aqueduct
was not observed any longer. When Dox was given continuously
until P60 and mice were again sacrificed at P90, X-Gal staining
revealed extensive staining in the brain stem and mid brain where
serotonergic neurons are located (Table 3: protocol 4;
Fig. 8D,H,L). Dual-label IHC confirmed that the majority of 5-
HT neurons (TPH2+) showed recombination by bgal expression
(.90%) while bgal expression outside the raphe nuclei was absent
confirming serotonergic tissue-specificity (Fig. 8P,T,X).
Previously, TPH2 expression was reported in the enteric
nervous system [18,19]. We used TPH2-tTA/Ptet-Cre/R26R
mice (P21) which had never received Dox to determine bgal
expression in the gut by IHC. On coronal sections throughout the
gastrointestinal system we could not detect bgal staining which
suggests that transgenic TPH2-tTA mice do not express the
transactivator in enteric neurons.
Discussion
In this study, we describe a TPH2-tTA mouse line which allows
efficient, Dox-repressible, Ptet-controlled gene expression in
serotonergic neurons of the brain. We demonstrate the function-
ality and feasibility of our approach by generating transgenic
Table 3. Protocols for inducible recombination in TPH2-tTA/
Ptet-Cre/R26R mice.
Protocol 1: Protocol 2: Protocol 3: Protocol 4:
hDox +Dox +/hDox postnatal +/h Dox adult
hDox until P90 +Dox until P90 +Dox until P0 +Dox until P60
hDox until P90 hDox until P90
Dox was administered with 5 mg/ml from initiation of matings until birth. At P0,
Dox concentration was changed to 50 mg/ml. In protocol 1, transgenic mice
were maintained in the absence of Dox throughout life until sacrifice at P90. In
protocol 2, mice were maintained under chronic Dox administration
throughout life until sacrifice at P90. In protocol 3, Dox was given from
conception until P0 when it was withdrawn until sacrifice at P90. In protocol 4,
Dox was given from conception until P60 when Dox was withdrawn until
sacrifice at P90. +Dox, administration of Doxycycline; hDox, no administration of
Dox.
doi:10.1371/journal.pone.0038193.t003
Figure 6. Functional characterization of Ptet-controlled, Cre-mediated recombination in TPH2-tTA/Ptet-Cre/R26R mice. TPH2-tTA
mice were mated with Ptet-Cre/R26R mice to generate triple-transgenic TPH2-tTA/Ptet-Cre/R26R mice. In Ptet-Cre mice, a bidirectional promoter
Ptetbi allows co-regulated Ptet-controlled transcription of Cre and luciferase cDNA. Luciferase activity can be used to indirectly quantify tissue-
specific Cre expression but was not needed to assess Cre-mediated recombination. In the presence of Dox (+Dox), Ptet-controlled Cre expression
does not occur. In the absence of Dox (2Dox), tTA activates Ptet-controlled Cre expression. Cre then deletes a loxP-flanked stop cassette in the
Rosa26 locus, thereby initiating bgal expression which indicates successful Cre-mediated recombination.
doi:10.1371/journal.pone.0038193.g006
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e38193Figure 7. Embryonic serotonergic recombination in TPH2-tTA/Ptet-Cre/R26R mice. In the absence of Dox, Ptet-controlled, Cre-mediated
recombination was analyzed in the embryonic brain. Double-fluorescence IHC with bgal- and 5-HT neuron-specific TPH2 antibodies was done in
brains from embryos at E12.5–E15.5. Already at E12.5, extensive bgal-staining was observed in developing 5-HT neurons (A,C,E). Later during
development at E15.5, X-Gal staining allows easy visualization of the strong and ubiquitous bgal activity in caudal (B), dorsal (D) and median (D,F)
raphe nuclei.
doi:10.1371/journal.pone.0038193.g007
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e38193TPH2-tTA/reporter mice which either show activatable and
reversible 5-HT neuron specific gene overexpression or inducible
Cre-mediated gene deletion at any time during development and
adulthood.
Transgenic 5-HT Neuron-specific Regulation of Candidate
Genes
For the 5-HT system, recent advances have led to the
identification of tissue-specific promoter sequences which allow
Cre and CreERT2 expression exclusively in serotonergic neurons
[20,21,22,23,24]. 5-HT specific gene deletion has led to a wealth
of new findings regarding the development and functioning of the
5-HT system in physiological and pathophysiological processes
[20,25,26,27,28,29]. However, for the better understanding of the
diverse functions of the 5-HT system, it will not only be of interest
to delete genes, but also to enhance the expression of certain genes
or even to induce serotonergic misexpression. To achieve this task,
the most applied gene regulatory system in transgenic animals is
the tet-system [30]. Tissue-specific promoters have been success-
fully employed to spatially control transactivator expression in the
brain of transgenic mice [31,32,33,34,35,36,37,38] but a 5-HT
neuron specific transactivator line has not been published to date.
Expression of TPH2 begins at E11 and persists throughout life
[18]. Its expression is restricted to serotonergic raphe nuclei in the
mid brain and brain stem [39]. In this study we implemented
regulatory sequences of the brain specific Tph2 gene [39] to
ensure cell-type specific serotonergic tTA expression. The 177 kb
PAC-derived DNA fragment containing the entire mouse Tph2
gene plus additional large flanking regions reliably directed tTA
expression solely to serotonergic neurons in postnatal and adult
mice. The same Tph2 DNA sequence was previously shown to
adequately control CreERT2 expression in serotonergic neurons
of transgenic TPH2-CreERT2 mice and rats [21,40]. During
embryonic development, we found transgenic expression in a small
number of TPH2-negative cells of the median raphe nuclei when
TPH2-tTA mice (-Dox) or TPH2-CreERT2 mice (+ tamoxifen
E15–18) [21] were studied. This may indicate aberrant embryonic
tTA- or CreERT2 expression due to missing regulatory elements
of the TPH2-construct specific for the embryonic phase.
Alternatively, the close anatomical relationship of bgal+/TPH2-
negative cells with bgal+/TPH2+5-HT neurons may indicate that
there is a transient embryonic TPH2 expression in non-
serotonergic cells in the raphe nuclei or that some originally
serotonergic cells convert to non-serotonergic neurons.
The TPH2-tTA Line 62-20 Allows Inducible and Reversible
Ptet-controlled Gene Expression
The generation of transgenic transactivator and tet-response
lines is sensitive to various factors influencing its regulatory
potential [41,42,43]. This comes as no surprise as the regulatory
magnificence, allowing for activatable and reversible gene
expression, relies heavily on its permanent controllability. Com-
pared to the Cre/loxP system which induces an irreversible
process of gene activation or gene deletion by excising loxP-
flanked DNA sequences, the tet-system requires permanent tTA
activation of the tet-promoter to transcribe the Ptet-controlled
transgene. This process requires sufficient levels of tissue-specific
tTA expression and constant accessibility of the Ptet-transgenic
locus, also after prolonged periods of silencing with Dox.
Both the transactivator and the Ptet transgene are sensitive to
genomic position integration effects, in particular if small plasmid-
based DNA sequences are microinjected [42]. This holds true for
any randomly integrated transgene but is particularly worrisome
in an inducible system which requires two transgenes to optimally
work together. Position effects can be minimized by using large
genomic sequences to drive transactivator or Ptet-controlled gene
expression [42,44]. For that reason, we used a large genomic Tph2
sequence to insulate tTA expression from position effects. As
expected, this strategy ensured faithful tissue-specific serotonergic
expression in 8 of 11 lines.
Variable Ptet-controlled gene expression has been observed in
sibling mice carrying identical transgenes inherited from the same
parents [42,45,46]. Similar gene expression variegation was also
found in most of our TPH2-tTA founder lines. Extensive
expression screening of double-transgenic TPH2-tTA/Ptet-nLacZ
litters from all functional TPH2-tTA lines identified one TPH2-
tTA line (L62-20) which showed robust Ptet-controlled transgene
expression. Apart from efficient reporter gene expression in more
than 80% of 5-HT neurons, expression variability among double-
transgenic offspring was very low and Ptet-controlled gene
expression could be turned on and off at will.
Hence, the characteristics of the TPH2-tTA line 62-20 allow for
reliable temporal control of candidate gene expression in the
majority of 5-HT neurons. Developmental suppression of Ptet-
controlled candidate gene expression and adult activation can be
important if one wishes to exclusively study the adult function of
a particular gene of interest and wishes to exclude developmental
effects of transgene expression. Indeed, overexpressing a protein
that serves essential functions during embryogenesis can result in
early lethality. Many genes also exert multiple functions in distinct
cell types during ontogeny and postnatally (pleiotropy). This may
result in complex phenotypes and, thereby, in difficulties in
distinguishing cell-autonomous from more complex origins of
abnormalities [47]. Finally, developmental transgene overexpres-
sion may also lead to adaptive changes during development. This
will either lead to the disappearance of an abnormal phenotype if
homeostasis has been achieved or to a phenotype that is not
directly related to the overexpressed gene but to the adaptive
changes caused by the manipulated gene. On the other hand,
Figure 8. Inducible, 5-HT neuron-specific recombination in TPH2-tTA/Ptet-Cre/R26R mice. Adult mice (P90) were sacrificed and analyzed
with X-Gal staining and IHC. (A–L) X-Gal staining of coronal sections of the brain stem and midbrain. (M–X) Dual-label fluorescence IHC with bgal and
5-HT neuron-specific TPH2 antibodies. Co-labelling indicates 5-HT neuron-specific recombination. Without Dox administration (2Dox), X-Gal staining
showed intense bgal activity in all areas of the raphe nuclei where 5-HT neurons are located (A,E,I). Dual-label IHC confirmed that bgal expression
occurs tissue-specifically in virtually all 5-HT neurons (M,Q,U). Of note, extraserotonergic bgal expression was found in the median raphe nuclei of
untreated mice (U, arrows). (B,F,J,N,R,V) With permanent Dox administration (+Dox), Cre-induced recombination and consequently bgal expression
did only occur in a minor fraction of 5-HT neurons of TPH2-tTA/Ptet-Cre/R26R mice (V, arrow). To assess inducibility of Cre-mediated recombination,
Dox was either administered during embryonic development until P0 (+Dox –P0; C,G,K,O,S,W) or during embryonic and postnatal development until
P60 (+Dox –P60; D,H,L,P,T,X), when Dox was withdrawn until sacrifice at P90. X-Gal staining showed equally strong bgal activity in the raphe nuclei of
TPH2-tTA/Ptet-Cre/R26R mice which were induced at P0 (C,G,K) or at P60 (D,H,L). As shown with IHC, recombination occurred tissue-specifically in the
majority of 5-HT neurons, irrespective of the time point of induction at P0 (O,S,W) or P60 (P,T,X). The efficiency of tissue-specific recombination was
indistinguishable from mice which never received Dox (M,Q,U) which proves that induction of Cre-mediated recombination after Dox suppression is
equally efficient. Of note, when Cre recombination was suppressed with Dox until P0, extraserotonergic recombination in the median raphe nuclei
could not be detected anymore (W,X). Grey arrowheads indicate scarce non-recombined, bgal-negative TPH2+5-HT neurons. Scale bars: 100 mm.
doi:10.1371/journal.pone.0038193.g008
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that allows reversibility of gene expression. While the CreERT2/
loxP system allows for temporal control of transgene expression via
tamoxifen treatment, these changes are irreversible compared to
transgenic expression using the tet-system. Shutting down gene
expression allows to assess whether induced phenotypic changes
are reversible or whether they persist independent of the initial
genetic manipulation [48,49,50,51]. Of note, while Ptet-controlled
gene expression can be rapidly suppressed with Dox within 1–2
days during embryonic [52,53] and postnatal [36] development as
well as during adulthood [42,54], gene activation after Dox
withdrawal cannot be initiated with the same speed at any stage
during life [36,37,42,54]. Variables which influence the delay
phase for activation of Ptet-controlled gene expression include the
choice of doxycycline or tetracycline for gene suppression [42],
duration of Dox treatment [36,51], Dox dosage [37,42] and tissue
involved [55,56]. Studies which used Dox concentrations between
50-2000 mg/ml found that earliest Ptet-controlled gene expression
commenced around 2–5 days after Dox withdrawal with full
activation of gene expression between 7 days and 8 weeks
[36,37,42,57]. Hence, the delay phase of Ptet-controlled gene
activation after Dox treatment is highly variable and appears to be
mostly dependent on the duration of Dox treatment and its dosage
[37,42,58]. In double-transgenic TPH2-tTA/Ptet-nLacZ and
triple-transgenic TPH2-tTA/Ptet-Cre/R26R mice which were
suppressed with 5 mg/ml Dox (to the mothers) from conception
until birth followed by 50 mg/ml until P60, we found partial
activation of bgal expression after 7 days and full activation after
3–4 weeks. Thus, the Dox withdrawal time point is not equivalent
to the initiation of effective Ptet-controlled gene expression. This
delay phase needs to be empirically determined if Ptet-controlled
gene expression in TPH2-tTA mice is intended to be initiated at
a certain point in time during development or adulthood.
Another concern of prolonged Dox administration during
embryonic development is the deposition of Dox in calcified
tissues of the embryo which is associated with bone growth
retardation [59]. Recently, a delay in bone growth has been shown
in rats treated with 8 mg/kg Dox from E8–19 [60]. We and many
others have never found growth deficits in mice treated with Dox
but can not rule out that a delay of skeletal differentiation occurs
during development. It has been reported that low dosages of Dox
do not result in clinically relevant blood levels and are thus unlikely
to produce deleterious effects [37]. During embryonic develop-
ment, we administer only 5 mg/ml Dox to pregnant mothers
which is to our knowledge the lowest Dox concentration so far
applied which sufficiently suppresses Ptet-controlled gene expres-
sion in vivo. Hence, pregnant TPH2-tTA mice and their fetuses
receive only 0.75–1.25 mg/kg/d Dox which is an approximately
10 times lower Dox dosage than previously reported [60].
TPH2-tTA Mice Allow Inducible Ptet-controlled, Cre-
mediated Gene Deletion
The tet-technology can be combined with the Cre/loxP system.
For this purpose, a tissue-specific transactivator line has to be bred
to a Cre line in which Cre expression is controlled by a tet-
promoter (Ptet-Cre). A powerful tool for this approach is the well
characterized LC-1 mouse line, where Ptet-controlled Cre
synthesis is tightly controlled yet highly inducible [12]. In many
aspects, this approach compares favorably to the widely used
tamoxifen-inducible CreERT2 system. Tamoxifen is a partial
estrogen/antiestrogen in humans and a full estrogen in mice [61].
In human and rodents, acute and late side effects (http://www.
nlm.nih.gov/medlineplus/druginfo/meds/a682414.html) have
been documented for this substance [62,63], so its application
cannot be presumed to be inert for transgenic mice. Hence,
molecular and cellular processes, in particular neuroendocrine
pathways, will be altered with tamoxifen administration.
In most studies, tamoxifen is administered via repeated
intraperitoneal (ip) injections or oral gavages which are both
stressful procedures for the mice. Regardless of the administration
route, tamoxifen administration during embryonic development is
problematic. It has been reported to cause spontaneous abortion
and intrauterine hemorrhage as well as developmental delay and
abnormal head development in the embryos [64,65]. It also
inhibits natural birth requiring standard caesarian section and
foster mothers for the pups of tamoxifen treated pregnant mice
[21,66,67]. Postnatally, the route of administration usually
requires repeated intraperitoneal injections or oral gavages to
the lactating mothers, which imposes significant stress to the
mothers and pups. While others have reported on successful
repeated intraperitoneal injections or oral gavages to lactating
mothers [64,68], in our hands this procedure has led to frequent
maternal abandonment of the pups. Although it has been shown
that adult tamoxifen administration had no effect on subsequent
testing of several behavioral parameters [69], it has not been
clarified whether this is also true for tamoxifen application during
development. Only recently, several studies reported on successful
recombination after administration of tamoxifen citrate via mouse
chow [70,71,72,73].
A sensible alternative to the inducible CreERT2 system to
circumvent tamoxifen side effects and stressful administration
routes is the generation of tissue-specific transactivator/Ptet-Cre
mice which allows inducible overexpression or gene deletion
without tamoxifen administration. In this study, we confirm the
feasibility of this approach by generating TPH2-tTA/Ptet-Cre/
R26R mice. Ptet-controlled Cre expression could be successfully
suppressed with oral Dox administration via drinking water at any
time during development and adulthood. Controlling Cre
expression limits recombinase activity to a defined time window
thereby avoiding Cre toxicity which occurs during prolonged Cre
expression [74]. Removing Dox from the drinking water resulted
in successful embryonic, postnatal or adulthood deletion of loxP
flanked DNA sequences allowing for an easy, non-interventional,
non-toxic, temporal control of gene deletion.
Transgenic TPH2-tTA mice provide an opportunity to study
highly efficient, inducible and reversible expression of Ptet-
controlled transgenes in 5-HT neurons. Moreover, in combination
with a Ptet-inducible Cre line we demonstrate an ‘‘all in one tool’’
which also allows Cre-mediated gene deletion selectively in
serotonergic neurons without any background recombination.
The option to inducibly express or delete the same candidate gene
diametrically at any time during life will promote the un-
derstanding of molecular, biochemical and behavioural effects of
time-specific gene manipulations within the serotonergic system.
Materials and Methods
Generation of Transgenic TPH2-tTA Mice
A modified 196 kb PAC [21] that contains the full-length mouse
Tph2 gene (107 kb) and 51 kb upstream and 19 kb downstream
DNA sequences was selected for recombineering in EL250
bacteria [14]. The stTA2 sequence was PCR amplified together
with the SV40 polyadenylation (polyA) site from the plasmid
pUHT 61-1 [75] and ligated into the pL451 vector [14]
harbouring a FRT flanked Neomycin/Kanamycin (Neo/Kan)
resistance cassette. The resulting stTA2.SV40polyA-FRT.Neo/
Kan.FRT-sequence was PCR-amplified using primers that com-
prised 42 bp of DNA-sequence homologous to the selected
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59-TGGTCCCCCCTGCTGCTGAGAAAGAAAATTA-
CATCGGGAGCCatgtctagactggacaagag caaag-39, downstream
primer 59-GAATCCAAGGACAACCCTCTCCTGGCCCAG-
TATTTACTGGAAatattatgtacctgactgatg aag-39). This DNA frag-
ment was used for homologous recombination of the tTA.polyA
sequence into the Tph2 start codon of the 196 kb PAC. A 23 bp
sequence starting with the ATG-translation start of Tph2 was
intentionally deleted since it contained additional in-frame ATG-
start sites. The PCR-product (200 ng) was electroporated into
EL250 bacterial cells containing the Chloramphenicol-resistent
pPAC4-L065 (pPAC4-Cam-L065) and homologous recombina-
tion was heat-induced. Next, Flp-mediated excision of the FRT-
flanked Kanamycin-resistence gene was achieved by Arabinose
induction. Finally, recombination of stTA2.pA into the ATG-start
of Exon 1 was verified by sequencing the entire stTA2-cassette plus
adjoining DNA sequences. Confirmation of the integrity of
pPAC4-Cam-L065-stTA2.pA after recombination was done with
XhoI digestion and Pulse-field gel electrophoresis (PFGE) analyses.
The tTA-modified genomic Tph2 sequence was separated from the
PAC backbone by NotI digestion and subsequent preparative
PFGE. The purified, linearized DNA fragment was microinjected
into the male pronucleus of BDF1 mouse oocytes.
For functional analysis of Ptet-controlled gene expression,
TPH2-tTA mice were mated to homozygous Ptet-nLacZ (NZL2)
mice [15] to generate double transgenic TPH2-tTA/Ptet-nLacZ
mice. For analysis of Ptet-controlled, Cre-mediated recombina-
tion, TPH2-tTA mice were mated to homozygous Ptet-Cre/R26R
mice [12,17] to generate triple-transgenic TPH2-tTA/Ptet-Cre/
R26R mice.
All experimental procedures were approved by the local Animal
Welfare Committee (Regierungspra ¨sidium Karlsruhe 35-9185.81/
G-107/09) and carried out in accordance with the local Animal
Welfare Act and the European Communities Council Directive of
24 November 1986 (86/609/EEC).
Doxycycline Treatment
Doxycycline (Dox) (Sigma) was dissolved in tab water
supplemented with 5% Sucrose. For Ptet-controlled suppression
of gene expression or Ptet-controlled, Cre-mediated gene deletion
during embryonic development, 5 mg/ml Dox was administered
via drinking water from the beginning of matings until birth.
Mice with continuous Dox suppression until adulthood were
given 5 mg/ml Dox in the drinking water from the beginning of
matings until birth and 50 mg/ml Dox from P0-P60. Dox
treatment in adult mice was always carried out with 50 mg/ml
Dox. Activation of Ptet-controlled gene expression or Ptet-
controlled, Cre-mediated gene deletion without Dox routinely
lasted for 30 days.
Non-radioactive in situ Hybridization
To generate a 700 bp cDNA tTA-template for antisense
riboprobes we incorporated a T7 promoter into the antisense
primer (tTA-Start: 59-ATG TCT AGA CTG GAC AAG AGC A-
39, T7-tTA Stop: 59-GTA ATA CGA CTC ATA GGG CAG CAG
GCA GCA-39). Plasmid pUHT 61-1 (Urlinger et al., 2000)
containing the full-length stTA2 cDNA was used for PCR. The
PCR-product was extracted with phenol/chloroform. RNA in
vitro transcription was performed using digoxigenin-labelled (DIG)
UTP (Roche). After 2 h incubation, DNase was added to digest
the DNA template. DIG-labelled UTP which was not incorpo-
rated into the RNA transcript was eliminated with NucAway Spin
columns (Ambion). TPH2-tTA mice from each founder line were
perfused with 4% paraformaldehyde (PFA) and postfixed for 8 h
in 4% PFA. Prior to in situ hybridization (ISH), 50 mm coronal
brain sections were cut on a vibratome and washed with 16PBS
and 16PBS/0.1%Triton-X. Prehybridization of brain sections
was carried out at 65uC for 1 h in hybridization buffer (25 ml
Formamide, 0.5 ml Yeast tRNA [10 mg/ml], 5 ml DEPC-PBS,
10 ml 206SSC, 5 ml Dextran 50%, 1 ml 506Denhard, 3.5 ml
DEPC-H2O) without the tTA-riboprobe. Afterwards the tTA-
riboprobe was denatured at 95uC for 2 min and 300 ng/ml were
used for hybridization in hybridization buffer for 18 h at 65uC.
The next day, brain sections were washed with descending
concentrations of SSC followed by two wash-steps with 16Dig-
solution (24.2 g Tris, 17.52 g NaCl, 148 ml 1 M HCL, 1260 ml
DEPC-H2O) plus 4% BSA/0.1% Triton-X and one wash-step
with 16Dig-solution plus 2% BSA/0.1% Triton-X. Thereafter,
the brain sections were incubated in 36Dig-solution (72.6 g Tris,
52.56 g NaCl, 444 ml 1 M HCl, 1260 ml DEPC-H2O) with 1/
750 anti-DIG-AP antibody (Dako) for 12 h at 4uC. The next day,
brain sections were washed repeatedly with 16Dig and 16TBS.
Finally, BCIP was added to a 16TBS/MgCl solution for 10–
30 min and the staining process was terminated with several
16PBS washes. Brain sections were mounted on slides with Eukitt
(Kindler GmbH, Freiburg, Germany).
Histology
For X-Gal staining, adult mice were perfused with 4% PFA and
postfixed with 0.2% Glutaraldehyde in lacZ fix solution (2 mM
MgCl, 5 mM EGTA in 100 mM sodium phosphate, pH 7.3) at
4uC for 8 hours. Brains from embryos were fixed with 4% PFA at
4uC for one hour. 50 mm coronal brain sections were cut on
a vibratome (Leica), washed with 16PBS and stained with X-Gal
staining solution (2 mM MgCl2, 5 mM K3[Fe(CN)6], 5 mM
K4[Fe(CN)6] and 1 mg/ml X-Gal in 16PBS) at 37uC for 1–4
hours and counterstained with Eosin (0.01 mg/ml 16PBS).
Immunohistochemistry
Adult mice were perfused with 4% PFA at 4uC. Brains were
postfixed with 4% PFA at 4uC for 24 hours. 50 mm coronal
sections were cut on a vibratome (Leica). Double-fluorescence
IHC was performed on floating sections.
Brains from TPH2-tTA/Ptet-Cre/R26R embryos were fixed
with 4% PFA at 4uC for 24 hours, dehydrated with sucrose (10%)
for another 24 hours and frozen at 280uC. Coronal sections
(20 mm) were cut on a kryostat (Leica CM 1950) and sections were
mounted on tissue slides (Super Frost Ultra Plus, Menzel Gla ¨ser,
Germany). Double-fluorescence IHC was performed in a humid
chamber.
For IHC of the gut, TPH2-TA/Ptet-Cre/R26R mice (P21)
were perfused with 4% PFA at 4uC. The entire body was postfixed
with 4% PFA at 4uC for 24 hours and dehydrated with sucrose
(10%) for another 24 hours and frozen at 280uC. 50 mm coronal
section of the entire gastrointestinal (GI) tract were cut on
a kryostat (Leica CM 1950) and sections were mounted on tissue
slides (Super Frost Ultra Plus, Menzel Gla ¨ser, Germany). Double-
fluorescence IHC was performed in a humid chamber. For tissue
slide IHC, sections were first rehydrated with 16PBS and blocked
with 10% donkey serum in 16PBS for 1 hour. For IHC with adult
floating sections, coronal sections were first permeabilized with
Triton X-100 (0.1%) for 30 min in 16PBS at 4uC. Sections were
then washed with 16PBS (36) and blocked with 10% donkey
serum in 16PBS for 1 hour. For both tissue slide and floating
section IHC, primary antibodies were added to the blocking
solution and incubated at 4uC overnight. After washing with
16PBS the sections were incubated in blocking solution contain-
ing the secondary antibodies for 1 hour at room temperature.
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fluorescence mounting medium. The following primary antibodies
were used: rabbit a-TPH2 (Dianova, 1:5.000 in postnatal mice
and 1:2000 in embryos) and chicken a-b-galactosidase (Abcam,
1:10.000). Secondary antibodies were AF488 donkey a-rabbit
(Invitrogen, 1:500) and Cy3 donkey a-chicken (Jackson Immuno,
1:1000). Coronal vibratome sections were examined using a Nikon
C1Si-CLSM confocal laser-scanning microscope (Nikon Imaging
Center, BioQuant, Heidelberg, Germany). Embryonal and GI-
tract sections were examined on a Leica TCS SP5 confocal laser-
scanning microscope (ZI, Mannheim, Germany).
Statistical Methods
Coronal slices of adult TPH2-tTA mice of each founder line
were processed with dual-label fluorescent IHC detecting bgal and
TPH2. Image stacks of all slices that showed TPH2 staining were
acquired using a confocal laser-scanning microscope. The ratio of
bgal +/TPH2+ neurons to all TPH2+ neurons was calculated
separately for caudal, median and dorsal raphe nuclei. Confi-
dence-bounds (CI) for expression efficacy in adult mice were
calculated using the Clopper-Pearson method based on signifi-
cance level 95.0% [76].
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